Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2Phase 3 Interventional Results available

Compassionate Use of Omegaven in Children

NCT02370251
Conditions
Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

NCT00753142
Conditions
Diabetes Mellitus, Type 2
Interventions
Intralipid 20%, Glucose infusion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Abscess
Interventions
Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage
Drug · Device · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Rochester, New York
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Reprometabolic Syndrome Mediates Subfertility in Obesity

NCT02653092
Conditions
Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions
Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
HIV Infections
Interventions
Fat Emulsion 2%, Fat Emulsion 20%
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Miami, Florida • East Orange, New Jersey
Conditions
Advanced Malignant Neoplasm
Interventions
Fat Emulsion, Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
General Anesthesia
Interventions
HSK3486, propofol, Placebo
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven, Omegaven
Dietary Supplement · Drug
Lead sponsor
Pediatrix
Other
Eligibility
14 Days to 2 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Conditions
Cholestasis, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Days to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Houston, Texas
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Liver Injury
Interventions
Omegaven™, Historical Controls
Drug · Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

NCT02406586
Conditions
Hypertension, Diabetes
Interventions
Salsalate, Carvedilol, Placebo, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Accepts healthy volunteers

The Mixed Meal Challenge Study

NCT05087823
Conditions
Cardiovascular Diseases, Hyperlipidemias
Interventions
Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
HIV Infections
Interventions
Fat Emulsion 2%, Fat Emulsion 20%
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
East Orange, New Jersey
Conditions
Breast Abscess
Interventions
Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy
Procedure · Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618
Conditions
Healthy, Type 2 Diabetes
Interventions
Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
Biological
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
Interventions
lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection, emulsification tSVF
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Colchester, Vermont
No Longer Available No phase listed Expanded access

Compassionate Use of Omegaven IV Fat Emulsion

NCT02477345
Conditions
Cholestasis, Liver Disease
Interventions
Omegaven IV
Drug
Lead sponsor
Northwell Health
Other
Eligibility
1 Day to 5 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Staten Island, New York
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)

NCT02697201
Conditions
Insulin Resistance
Interventions
Intralipid, Saline
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Healthy
Interventions
Somatostatin, Dextrose, Insulin, Intralipid
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023
Conditions
Type 2 Diabetes, Hypertension
Interventions
Rosiglitazone, Normal saline 0.9%, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia